Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial.
Fish oil has been used effectively in the treatment of cardiovascular disease via triglyceride reduction and inflammation modulation. This study aimed to assess the effects of fish oil on patients with nonalcoholic fatty liver disease (NAFLD) associated with hyperlipidemia. Eighty participants with...
Main Authors: | Yu Qin, Yong Zhou, Shi-Hui Chen, Xiao-Lan Zhao, Li Ran, Xiang-Long Zeng, Ying Wu, Jun-Li Chen, Chao Kang, Fu-Rong Shu, Qian-Yong Zhang, Man-Tian Mi |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4520650?pdf=render |
Similar Items
-
Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease
by: Raptis DD, et al.
Published: (2023-01-01) -
Fibroblast Growth Factor 21 is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Atherosclerotic Cardiovascular Events
by: Liang Wu, et al.
Published: (2020-06-01) -
Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease
by: Guangyu Wu, et al.
Published: (2017-07-01) -
Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.
by: Anna Alisi, et al.
Published: (2013-01-01) -
Development of resveratrol with thiolated alginate as a supplement to prevent nonalcoholic fatty liver disease (NAFLD)
by: Yong-Chen Ke, et al.
Published: (2022-03-01)